Skip to main content
Erschienen in: World Journal of Urology 7/2015

01.07.2015 | Original Article

Evaluation of the PI-RADS scoring system for mpMRI of the prostate: a whole-mount step-section analysis

verfasst von: Daniel Junker, Michael Quentin, Udo Nagele, Michael Edlinger, Jonathan Richenberg, Georg Schaefer, Michael Ladurner, Werner Jaschke, Wolfgang Horninger, Friedrich Aigner

Erschienen in: World Journal of Urology | Ausgabe 7/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Evaluation of the Prostate Imaging Reporting and Data System (PI-RADS) scoring system for classifying multi-parametric magnetic resonance imaging findings of the prostate using whole-mount step-section slides as reference standard.

Materials and methods

Prospective inclusion of 50 consecutive patients with biopsy-proven prostate cancer (PCa). All patients received a multi-parametric MRI of the prostate, consisting of T2-weighted, diffusion-weighted, and dynamic contrast-enhanced MRI. After prostatectomy, all prostates were prepared as whole-mount step-section slides. For each patient, six lesions were predefined on whole-mount step-sections according to a distinct scheme and the corresponding regions were identified on MRI. Each lesion then was scored on MRI according to PI-RADS by an experienced blinded uro-radiologist and compared with histopathological findings.

Results

PCa received significant (p < 0.01) higher overall PI-RADS scores (4.10 ± 0.75) compared with benign changes (2.00 ± 0.74). In the peripheral zone, each single modality score showed good diagnostic accuracy for PCa detection (area under the curve [AUC] > 0.90). When combining all single modality scores, an even higher discriminative ability of PCa detection (AUC = 0.97, 95 % CI 0.95–0.99) could be achieved. In contrast, in the transitional zone, dynamic contrast-enhanced MRI (DCE) showed very low diagnostic accuracy (AUC = 0.60). Regarding tumor malignancy, no high-grade PCa (Gleason >7a) was present at PI-RADS scores <4 and no Gleason 6 PCa at a PI-RADS score of 5.

Conclusion

The PI-RADS scoring system showed good diagnostic accuracy: Only PI-RADS 4 and 5 showed high-grade PCa. However, it seems necessary to revise the PI-RADS scoring system concerning DCE in the transitional zone.
Literatur
1.
Zurück zum Zitat De Rooij M, Hamoen EH, Fütterer JJ, Barentsz JO, Rovers MM (2014) Accuracy of Multiparametric MRI for prostate cancer detection: a meta-AnalysisMaarten. AJR Am J Roentgenol 202(2):343–351. doi:10.2214/AJR.13.11046 PubMedCrossRef De Rooij M, Hamoen EH, Fütterer JJ, Barentsz JO, Rovers MM (2014) Accuracy of Multiparametric MRI for prostate cancer detection: a meta-AnalysisMaarten. AJR Am J Roentgenol 202(2):343–351. doi:10.​2214/​AJR.​13.​11046 PubMedCrossRef
3.
Zurück zum Zitat Dickinson L, Ahmed HU, Allen C, Barentsz JO, Carey B, Futterer JJ, Heijmink SW, Hoskin P, Kirkham AP, Padhani AR, Persad R, Puech P, Punwani S, Sohaib A, Tombal B, Villers A, Emberton M (2012) Scoring systems used for the interpretation and reporting of multiparametric MRI for prostate cancer detection, localization, and characterization: could standardization lead to improved utilization of imaging within the diagnostic pathway? J Magn Reson Imaging 37(1):48–58. doi:10.1002/jmri.23689 PubMedCrossRef Dickinson L, Ahmed HU, Allen C, Barentsz JO, Carey B, Futterer JJ, Heijmink SW, Hoskin P, Kirkham AP, Padhani AR, Persad R, Puech P, Punwani S, Sohaib A, Tombal B, Villers A, Emberton M (2012) Scoring systems used for the interpretation and reporting of multiparametric MRI for prostate cancer detection, localization, and characterization: could standardization lead to improved utilization of imaging within the diagnostic pathway? J Magn Reson Imaging 37(1):48–58. doi:10.​1002/​jmri.​23689 PubMedCrossRef
5.
Zurück zum Zitat Schimmöller L, Quentin M, Arsov C, Lanzman RS, Hiester A, Rabenalt R, Antoch G, Albers P, Blondin D (2013) Inter-reader agreement of the ESUR score for prostate MRI using in-bore MRI-guided biopsies as the reference standard. Eur Radiol 23(11):3185–3190. doi:10.1007/s00330-013-2922-y PubMedCrossRef Schimmöller L, Quentin M, Arsov C, Lanzman RS, Hiester A, Rabenalt R, Antoch G, Albers P, Blondin D (2013) Inter-reader agreement of the ESUR score for prostate MRI using in-bore MRI-guided biopsies as the reference standard. Eur Radiol 23(11):3185–3190. doi:10.​1007/​s00330-013-2922-y PubMedCrossRef
6.
Zurück zum Zitat Rosenkrantz AB, Lim RP, Haghighi M, Somberg MB, Babb JS, Taneja SS (2013) Comparison of interreader reproducibility of the prostate imaging reporting and data system and likert scales for evaluation of multiparametric prostate MRI. AJR Am J Roentgenol 201(4):W612–W618. doi:10.2214/AJR.12.10173 PubMedCrossRef Rosenkrantz AB, Lim RP, Haghighi M, Somberg MB, Babb JS, Taneja SS (2013) Comparison of interreader reproducibility of the prostate imaging reporting and data system and likert scales for evaluation of multiparametric prostate MRI. AJR Am J Roentgenol 201(4):W612–W618. doi:10.​2214/​AJR.​12.​10173 PubMedCrossRef
7.
Zurück zum Zitat Kuru TH, Roethke MC, Rieker P, Roth W, Fenchel M, Hohenfellner M, Schlemmer HP, Hadaschik BA (2013) Histology core-specific evaluation of the European Society of Urogenital Radiology (ESUR) standardised scoring system of multiparametric magnetic resonance imaging (mpMRI) of the prostate. BJU Int 112(8):1054–1055. doi:10.1111/bju.12307 CrossRef Kuru TH, Roethke MC, Rieker P, Roth W, Fenchel M, Hohenfellner M, Schlemmer HP, Hadaschik BA (2013) Histology core-specific evaluation of the European Society of Urogenital Radiology (ESUR) standardised scoring system of multiparametric magnetic resonance imaging (mpMRI) of the prostate. BJU Int 112(8):1054–1055. doi:10.​1111/​bju.​12307 CrossRef
8.
Zurück zum Zitat Portalez D, Mozer P, Cornud F, Renard-Penna R, Misrai V, Thoulouzan M, Malavaud B (2012) Validation of the European Society of Urogenital Radiology scoring system for prostate cancer diagnosis on multiparametric magnetic resonance imaging in a cohort of repeat biopsy patients. Eur Urol 62(6):986–996. doi:10.1016/j.eururo.2012.06.044 PubMedCrossRef Portalez D, Mozer P, Cornud F, Renard-Penna R, Misrai V, Thoulouzan M, Malavaud B (2012) Validation of the European Society of Urogenital Radiology scoring system for prostate cancer diagnosis on multiparametric magnetic resonance imaging in a cohort of repeat biopsy patients. Eur Urol 62(6):986–996. doi:10.​1016/​j.​eururo.​2012.​06.​044 PubMedCrossRef
9.
Zurück zum Zitat Roethke MC, Kuru TH, Schultze S, Tichy D, Kopp-Schneider A, Fenchel M, Schlemmer HP, Hadaschik BA (2014) Evaluation of the ESUR PI-RADS scoring system for multiparametric MRI of the prostate with targeted MR/TRUS fusion-guided biopsy at 3.0 Tesla. Eur Radiol 24(2):344–352. doi:10.1007/s00330-013-3017-5 PubMedCrossRef Roethke MC, Kuru TH, Schultze S, Tichy D, Kopp-Schneider A, Fenchel M, Schlemmer HP, Hadaschik BA (2014) Evaluation of the ESUR PI-RADS scoring system for multiparametric MRI of the prostate with targeted MR/TRUS fusion-guided biopsy at 3.0 Tesla. Eur Radiol 24(2):344–352. doi:10.​1007/​s00330-013-3017-5 PubMedCrossRef
10.
Zurück zum Zitat Junker D, Schäfer G, Edlinger M, Kremser C, Bektic J, Horninger W, Jaschke W, Aigner F (2013) Evaluation of the PI-RADS scoring system for classifying mpMRI findings in men with suspicion of prostate cancer. Biomed Res Int 2013:252939. doi:10.1155/2013/252939 PubMedCentralPubMedCrossRef Junker D, Schäfer G, Edlinger M, Kremser C, Bektic J, Horninger W, Jaschke W, Aigner F (2013) Evaluation of the PI-RADS scoring system for classifying mpMRI findings in men with suspicion of prostate cancer. Biomed Res Int 2013:252939. doi:10.​1155/​2013/​252939 PubMedCentralPubMedCrossRef
11.
Zurück zum Zitat Roethke M, Blondin D, Schlemmer HP, Franiel T (2013) PI-RADS classification: structured reporting for MRI of the prostate. RoFo. Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin 185(3):253–261. doi:10.1055/s-0032-1330270 CrossRef Roethke M, Blondin D, Schlemmer HP, Franiel T (2013) PI-RADS classification: structured reporting for MRI of the prostate. RoFo. Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin 185(3):253–261. doi:10.​1055/​s-0032-1330270 CrossRef
12.
Zurück zum Zitat Hoeks CM, Somford DM, van Oort IM, Vergunst H, Oddens JR, Smits GA, Roobol MJ, Bul M, Hambrock T, Witjes JA, Fütterer JJ, Hulsbergen-van de Kaa CA, Barentsz JO (2014) Value of 3-T multiparametric magnetic resonance imaging and magnetic resonance-guided biopsy for early risk restratification in active surveillance of low-risk prostate cancer: a prospective multicenter cohort study. Invest Radiol 49(3):165–172. doi:10.1097/RLI.0000000000000008 PubMedCrossRef Hoeks CM, Somford DM, van Oort IM, Vergunst H, Oddens JR, Smits GA, Roobol MJ, Bul M, Hambrock T, Witjes JA, Fütterer JJ, Hulsbergen-van de Kaa CA, Barentsz JO (2014) Value of 3-T multiparametric magnetic resonance imaging and magnetic resonance-guided biopsy for early risk restratification in active surveillance of low-risk prostate cancer: a prospective multicenter cohort study. Invest Radiol 49(3):165–172. doi:10.​1097/​RLI.​0000000000000008​ PubMedCrossRef
13.
Zurück zum Zitat D’Orsi CJ, Newell MS (2007) BI-RADS decoded: detailed guidance on potentially confusing issues. Radiol Clin North Am 45:751–763PubMedCrossRef D’Orsi CJ, Newell MS (2007) BI-RADS decoded: detailed guidance on potentially confusing issues. Radiol Clin North Am 45:751–763PubMedCrossRef
14.
15.
Zurück zum Zitat Haffner J, Lemaitre L, Puech P, Haber GP, Leroy X, Jones JS, Villers A (2011) Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection. BJU Int 108(8 Pt 2):E171–E178. doi:10.1111/j.1464-410X.2011.10112.x PubMedCrossRef Haffner J, Lemaitre L, Puech P, Haber GP, Leroy X, Jones JS, Villers A (2011) Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection. BJU Int 108(8 Pt 2):E171–E178. doi:10.​1111/​j.​1464-410X.​2011.​10112.​x PubMedCrossRef
16.
Zurück zum Zitat Parker C, Muston D, Melia J, Moss S, Dearnaley D (2006) A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. Br J Cancer 94(10):1361–1368PubMedCentralPubMedCrossRef Parker C, Muston D, Melia J, Moss S, Dearnaley D (2006) A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. Br J Cancer 94(10):1361–1368PubMedCentralPubMedCrossRef
17.
Zurück zum Zitat Wolters T, Roobol MJ, Leeuwen PJV, van den Bergh RC, Hoedemaeker RF, van Leenders GJ, Schröder FH, van der Kwast TH (2011) A Critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial. J Urol 185(1):121–125. doi:10.1016/j.juro.2010.08.082 Wolters T, Roobol MJ, Leeuwen PJV, van den Bergh RC, Hoedemaeker RF, van Leenders GJ, Schröder FH, van der Kwast TH (2011) A Critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial. J Urol 185(1):121–125. doi:10.​1016/​j.​juro.​2010.​08.​082
18.
Zurück zum Zitat Kirkham AP, Haslam P, Keanie JY, McCafferty I, Padhani AR, Punwani S, Richenberg J, Rottenberg G, Sohaib A, Thompson P, Turnbull LW, Kurban L, Sahdev A, Clements R, Carey BM, Allen C (2013) Prostate MRI: who, when, and how? Report from a UK consensus meeting. Clin Radiol 68(10):1016–1023. doi:10.1016/j.crad.2013.03.030 PubMedCrossRef Kirkham AP, Haslam P, Keanie JY, McCafferty I, Padhani AR, Punwani S, Richenberg J, Rottenberg G, Sohaib A, Thompson P, Turnbull LW, Kurban L, Sahdev A, Clements R, Carey BM, Allen C (2013) Prostate MRI: who, when, and how? Report from a UK consensus meeting. Clin Radiol 68(10):1016–1023. doi:10.​1016/​j.​crad.​2013.​03.​030 PubMedCrossRef
19.
Zurück zum Zitat Langer DL, van der Kwast TH, Evans AJ, Trachtenberg J, Wilson BC, Haider MA (2009) Prostate cancer detection with multi-parametric MRI: logistic regression analysis of quantitative T2, diffusion-weighted imaging, and dynamic contrast-enhanced MRI. J Magn Reson Imaging 30(2):327–334. doi:10.1002/jmri.21824 PubMedCrossRef Langer DL, van der Kwast TH, Evans AJ, Trachtenberg J, Wilson BC, Haider MA (2009) Prostate cancer detection with multi-parametric MRI: logistic regression analysis of quantitative T2, diffusion-weighted imaging, and dynamic contrast-enhanced MRI. J Magn Reson Imaging 30(2):327–334. doi:10.​1002/​jmri.​21824 PubMedCrossRef
20.
Zurück zum Zitat Oto A, Kayhan A, Jiang Y, Tretiakova M, Yang C, Antic T, Dahi F, Shalhav AL, Karczmar G, Stadler WM (2010) Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging. Radiology 257(3):715–723. doi:10.1148/radiol.10100021 PubMedCrossRef Oto A, Kayhan A, Jiang Y, Tretiakova M, Yang C, Antic T, Dahi F, Shalhav AL, Karczmar G, Stadler WM (2010) Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging. Radiology 257(3):715–723. doi:10.​1148/​radiol.​10100021 PubMedCrossRef
21.
Zurück zum Zitat Rosenkrantz AB, Kim S, Lim RP, Hindman N, Deng FM, Babb JS, Taneja SS (2013) Prostate cancer localization using multiparametric MR imaging: comparison of Prostate Imaging Reporting and Data System (PI-RADS) and Likert scales. Radiology 269(2):482–492. doi:10.1148/radiol.13122233 PubMedCrossRef Rosenkrantz AB, Kim S, Lim RP, Hindman N, Deng FM, Babb JS, Taneja SS (2013) Prostate cancer localization using multiparametric MR imaging: comparison of Prostate Imaging Reporting and Data System (PI-RADS) and Likert scales. Radiology 269(2):482–492. doi:10.​1148/​radiol.​13122233 PubMedCrossRef
22.
Zurück zum Zitat Westphalen AC, Rosenkrantz AB (2014) Prostate imaging reporting and data system (PI-RADS): reflections on early experience with a standardized interpretation scheme for multiparametric prostate MRI. AJR Am J Roentgenol 202(1):121–123. doi:10.2214/AJR.13.10889 PubMedCrossRef Westphalen AC, Rosenkrantz AB (2014) Prostate imaging reporting and data system (PI-RADS): reflections on early experience with a standardized interpretation scheme for multiparametric prostate MRI. AJR Am J Roentgenol 202(1):121–123. doi:10.​2214/​AJR.​13.​10889 PubMedCrossRef
Metadaten
Titel
Evaluation of the PI-RADS scoring system for mpMRI of the prostate: a whole-mount step-section analysis
verfasst von
Daniel Junker
Michael Quentin
Udo Nagele
Michael Edlinger
Jonathan Richenberg
Georg Schaefer
Michael Ladurner
Werner Jaschke
Wolfgang Horninger
Friedrich Aigner
Publikationsdatum
01.07.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
World Journal of Urology / Ausgabe 7/2015
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-014-1370-x

Weitere Artikel der Ausgabe 7/2015

World Journal of Urology 7/2015 Zur Ausgabe

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Männern mit Zystitis Schmalband-Antibiotika verordnen

03.05.2024 Zystitis Nachrichten

Die akute Zystitis von Männern und ihre Therapie sind wenig erforscht. Norwegische Forscher haben das nachgeholt. Ihr Rat: Erst einmal keine Breitbandantibiotika verordnen.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.